SOTROVIMAB FOR INJECTION

GlaxoSmithKline Inc🇨🇦 Health Canada

Approval Id: ad7b038502266449
Drug Approval Canada Name: SOTROVIMAB FOR INJECTION
Product Name: SOTROVIMAB FOR INJECTION
Status: Authorization By Interim Order Revoked
Status Date: 2024-04-29
Original Market Date: 2021-10-08
Din: 02518341
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Intravenous
Schedule: Schedule D , COVID-19 - IO - Authorization , Prescription
Ahfs: 08:18.24
Atc Original: J06BD05 SOTROVIMAB
Atc Name: j 06 bd 05
Aig Number: 0163072001
Company Name: GlaxoSmithKline Inc
Company Address: 800, 100 Milverton Drive, Mississauga, Ontario, Canada, L5R 4H1
Company Detail Path: /organization/glaxosmithkline-inc

SOTROVIMAB

500 MG / 8 ML

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

ad7b038502266449

Type

Standard